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Background: The rare autosomal genetic disorder, Spondylo-meta-epiphyseal dysplasia with short limbs and abnormal
calcifications (SMED-SL), is reported to be caused by missense or splice site mutations in the human discoidin domain
receptor 2 (DDR2) gene. Previously our group has established that trafficking defects and loss of ligand binding are the
underlying cellular mechanisms of several SMED-SL causing mutations. Here we report the clinical characteristics of two
siblings of consanguineous marriage with suspected SMED-SL and identification of a novel disease-causing mutation in
the DDR2 gene.
Methods: Clinical evaluation and radiography were performed to evaluate the patients. All the coding exons and splice
sites of the DDR2 gene were sequenced by Sanger sequencing. Subcellular localization of the mutated DDR2 protein
was determined by confocal microscopy, deglycosylation assay and Western blotting. DDR2 activity was measured by
collagen activation and Western analysis.
Results: In addition to the typical features of SMED-SL, one of the patients has an eye phenotype including visual
impairment due to optic atrophy. DNA sequencing revealed a novel homozygous dinucleotide deletion mutation
(c.2468_2469delCT) on exon 18 of the DDR2 gene in both patients. The mutation resulted in a frameshift leading
to an amino acid change at position S823 and a predicted premature termination of translation (p.S823Cfs*2).
Subcellular localization of the mutant protein was analyzed in mammalian cell lines, and it was found to be largely
retained in the endoplasmic reticulum (ER), which was further supported by its N-glycosylation profile. In keeping
with its cellular mis-localization, the mutant protein was found to be deficient in collagen-induced receptor
activation, suggesting protein trafficking defects as the major cellular mechanism underlying the loss of DDR2
function in our patients.
Conclusions: Our results indicate that the novel mutation results in defective trafficking of the DDR2 protein
leading to loss of function and disease. This confirms our previous findings that DDR2 missense mutations
occurring at the kinase domain result in retention of the mutant protein in the ER.
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Spondylo-meta-epiphyseal dysplasia (SMED), short limb-
hand type (SMED-SL, OMIM 271665) is a rare autosomal
recessive disorder affecting human skeletal growth. The
condition is characterized by disproportionately short stat-
ure, platispondyly, abnormal epiphyses and metaphyses,
shortening of the lower and upper limbs, short broad fin-
gers and punctate calcifications [1-4]. This bone dysplasia is
progressive, with serious complications leading to death in
some cases. Atlantoaxial instability resulting in cord
damage has been the most reported cause of death [2,5].
Homozygous mutations occurring in the Discoidin do-
main receptor 2 gene (DDR2, MIM 191311) have been
identified as the cause for this severely dwarfing condi-
tion [6,7]. The DDR2 gene encodes one of the two
members of a unique receptor tyrosine kinase (RTK)
subfamily known as the discoidin domain containing
receptors (DDRs), which recognize collagen as their
ligands [8,9]. Upon collagen binding, the receptor dis-
plays delayed and sustained tyrosine phosphorylation
which further elicits downstream signalling to cellular
metabolic pathways that cross-talk at various points
[10,11]. In addition, dysregulation of DDR2 has been
shown to be associated with various human diseases
such as fibrosis, arthritis and cancer and like other
RTKs, DDRs are emerging as potential therapeutic tar-
gets [12].
DDR2 is commonly expressed in cells of mesenchymal
origin and is activated by fibrillar collagens [8,9] and col-
lagen X [13]. DDR2 has been shown to play a critical
role in cell invasion and collagen remodelling through
the regulation of matrix metalloproteases and collagen
fibrillogenesis [10,14-16]. The involvement of DDR2 in
skeletal growth was demonstrated by the DDR2 knockout
mice, which display skeletal abnormalities that reflect the
SMED-SL phenotype of humans [17]. The abnormal skel-
etal development in DDR2 deficient mice was due to
reduced chondrocyte proliferation in the growth plate. A
spontaneous, autosomal recessive mutation in a mouse col-
ony was characterised that resulted from deletion of most
of the Ddr2 gene [18]. These mutant mice were also found
to be infertile due to gonadal dysfunction including im-
paired spermatogenesis and ovulation, which were attrib-
uted to defects in overall endocrine function [18-20].
DDRs are plasma membrane RTKs comprising an
extracellular domain (ECD), a transmembrane domain
(TM), a large cytosolic juxtamembrane domain and a C-
terminal catalytic tyrosine kinase domain. The ECD is
necessary and sufficient for ligand binding and consists of
an N-terminal discoidin homology (DS) domain followed
by a region unique to the DDRs that contains a DS-like do-
main [21-23]. The DDRs exist as preformed homodimers
on the cell membrane even in the absence of collagen
[24,25]. The exact signaling pathways and binding partnersthrough which DDR2 controls bone growth remain un-
known despite significant progress made in recent years in
understanding the structural basis of collagen recognition
[26]. In recent reports it was shown that DDR2 modulates
the phosphorylation of Runx2, a master transcription fac-
tor involved in skeletal development [27,28]. In addition,
DDR2 has been shown to mediate the secretion of lysyl
oxidase [29], an enzyme that catalyzes cross-linking of col-
lagen fibers, an essential modification to strengthen bone.
A recent study has shown that the DDR2 ECD aids
the formation of mineralized calcium deposits in vitro,
and this activity is independent of the tyrosine kinase ac-
tivity [16]. The authors proposed that the presence of
DDR2 ECD in the mutant proteins along with impaired
signaling leading to increased calcification could be a
potential mechanism in SMED-SL. Mutations prevalent
in SMED-SL disorder have been mapped to the extracel-
lular domain and tyrosine kinase domain of DDR2 [6,7].
Recently we have shown that DDR2 missense mutations
occurring at the kinase domain (p.T713I, p.I176R, p.
R752C) result in retention of the mutant protein in the
endoplasmic reticulum (ER), while the ectodomain mu-
tant (p.E113K) is expressed on the cell surface, but failed
to bind to collagen, thus elucidating two different cellu-
lar mechanisms resulting in loss of function of the pro-
tein leading to disease [7].
ER retention of misfolded proteins and subsequent
degradation (ERAD) is a recurring theme in many skeletal
disorders [30-33] and numerous other monogenic diseases
[31,34-36]. Inhibition of ERAD coupled with proteostasis
modulation has been shown to enhance folding, trafficking
and activity of unstable proteins and is emerging as a po-
tential strategy to combat many protein misfolding disor-
ders [37]. Defining the potential contribution of specific
mutations and intracellular stress to the pathophysiology of
the disease will pave avenues for targeted therapeutic inter-
vention and disease management in the future.
We report here the clinical and molecular findings in
SMED-SL patients of consanguineous origin from Oman
and the identification of a novel disease-causing truncat-
ing mutation in DDR2. The sub-cellular localization and
functional status of the mutant and wild type proteins
were compared in a mammalian expression system. Our
results indicate that the novel mutation results in defect-
ive trafficking of the protein and loss of its activation by
collagen.Methods
Clinical evaluations
This study complies with the Helsinki Declaration and has
been approved by Al-Ain District Human Research Ethics
Committees (protocol No. AAMD/HREC 10/09) and the
family provided an informed consent. Clinical assessment
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imaging of the subjects was also evaluated.
Chemicals and reagents
Collagen I (acid-soluble from rat tail) was from Sigma
(Gillingham, UK). The antibodies and their sources were
as follows: antibodies for immunofluorescence: mouse
anti-HA-tag monoclonal antibody (dilution 1:200; Cell
Signaling Technology), rabbit anti-calnexin polyclonal
antibody (dilution 1:200, Santa Cruz), Alexa Fluor 568-goat
anti-mouse IgG (dilution 1:200; Molecular Probes), Alexa
Fluor 568-goat anti-rabbit IgG (dilution 1:200; Molecular
Probes), Alexa Fluor 488-goat anti mouse IgG (dilution
1:200, Molecular Probes). Antibodies for Western blotting:
goat anti-DDR2 from R & D Systems (Abingdon, UK);
mouse anti-phosphotyrosine, clone 4G10, from Upstate
Biotechnology (Lake Placid, NY); sheep anti-mouse
Ig-horseradish peroxidase (Amersham Biosciences UK,
Chalfont St Giles, UK); rabbit anti-goat Ig-horseradish
peroxidase (Zymed Laboratories, San Francisco, CA).
Mutation screening
Genomic DNA was extracted from peripheral leukocytes
using the Flexigene DNA kit (Qiagen). The coding exons
and exon-flanking sequences were analyzed by PCR (Taq
polymerase, Qiagen) followed by direct sequencing using
the BigDye Terminator v3.1 Cycle Sequencing kit (Applied
Biosystems, Foster City, CA). Capillary electrophoresis
was performed on an ABI PRISM 3130xl DNA Analyzer
(Applied Biosystems). Primers and PCR conditions for
amplification of the coding exons (Exons 3–18) and splice
sites have been described previously [7]. Sequences were
aligned to the NCBI reference sequence NM_001014796,
using ClustalW2 algorithm and mutations were designated
with reference to the translation start site.
Generation of mammalian expression constructs
The frame-shift mutation, c.2468_2469delCT was in-
troduced into the untagged expression vector, pcDNA3.1-
DDR2 [22] by site directed mutagenesis using Pfu Ultra
HF polymerase (Stratagene, La Jolla, CA). The primers used
were: DDR2-S823Cfs*-F: CATTTGTCCTGACTGTGTA
TAAGCTGATG, DDR2-S823Cfs*-R: CATCAGCTTATA
CACAGTCAGGACAAATG. This construct was subse-
quently used for performing deglycosylation and recep-
tor binding assays. An HA tag was inserted prior to the
stop codon (introduced by the frame-shift mutation) of
the mutated construct, using two cycles of site directed
mutagenesis. In the first cycle, the initial five amino
acids (YPYDV) of the HA tag were introduced at the
C-terminus of the mutated DDR2, using the primers:
DDR2_Mut2A_FP: GTCCTGACTGTGTATACCCATA
CGATGTTTAAGCTGATGCTCAGCTG, DDR2_Mu-
t2A_RP: CAGCTGAGCATCAGCTTAAACATCGTATGGGTATACACAGTCAGGAC. The remaining four
amino acids (PDYA) of the tag were introduced to the




TAT. All the plasmids have been sequenced to confirm
the introduction of intended changes.
Cell culture and transfection
HeLa cells were cultured in DMEM (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine and 100 U/ml penicillin/streptomycin at 37°C
with 5% CO2. For localization experiments, cells were
grown on sterile cover slips in 24-well tissue culture plates
and transient transfection was performed by FuGENE HD
transfection reagent according to the manufacturer’s in-
structions (Promega, Madison, WI) using 0.5 μg plasmid
DNA. GFP-H-Ras plasmid was used as a plasma membrane
marker and co-transfected with HA-tagged wild type or
mutant plasmids. The cells were processed for staining and
imaging after 24 hours of transfection.
Human embryonic kidney (HEK-293) cells (ATCC,
Manassas, VA, USA) were cultured in Dulbecco’s modified
Eagle’s medium/F12 medium (Invitrogen) supplemented
with 10% fetal bovine serum (Invitrogen), penicillin (10 U/
ml) and streptomycin (100 μg/ml) at 37°C with 5% CO2.
For transfection, cells were grown in 24-well tissue cul-
ture plates and were transfected with untagged DDR2
wild-type or mutant plasmid DNA using calcium phos-
phate precipitation.
Immunocytochemistry and imaging
Twenty-four hours after transfection, HeLa cells grown
on cover slips were washed with phosphate-buffered sa-
line (PBS) and fixed by methanol at 22°C for 5 min.
Fixed cells were washed in PBS three times and blocking
was carried out in 1% BSA (Sigma) in PBS for 30 min at
room temperature. After blocking, the cells were incu-
bated with either mouse monoclonal anti-HA antibody
alone or co-stained with both mouse monoclonal anti-HA
antibody and rabbit polyclonal anti-calnexin antibodies, for
45 min at room temperature. The cells were washed with
PBS, and incubated with the respective secondary anti-
bodies for 45 min at room temperature, washed several
times with PBS and mounted in immunofluor medium
(ICN Biomedicals). Confocal microscopy and imaging was
performed with a Nikon Eclipse system (Nikon Instruments
Inc., Melville, NY).
Collagen-induced DDR2 autophosphorylation
The assay was performed as described previously in de-
tails [22]. Twenty-four hours after transfection, HEK-293
cells were incubated with serum-free medium for 16 h.
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90 min at 37°C. Cells were lysed in 1% Nonidet P-40,
150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 50 μg/ml aprotinin, 1 mM
sodium orthovanadate and 5 mM NaF. Aliquots of the ly-
sates were analyzed by SDS–PAGE followed by blotting
onto nitrocellulose membranes. The duplicate blots were
probed with either anti-phosphotyrosine monoclonal anti-
body or anti-DDR2 antibodies followed by corresponding
horseradish peroxidise-conjugated secondary antibodies.
Detection was performed using Pierce ECL 2 Western
Blotting substrate (Thermo Scientific) and an Ettan DIGE
Imager (GE Healthcare Biosciences).
Endoglycosidase H deglycosylation assay
Forty eight hours after transfection, HEK-293 cells were
lysed as described above. Twenty microliter of each cell
lysate was denatured in 1× glycoprotein denaturing buf-
fer (0.5% SDS and 1% β-mercaptoethanol) for 5 min at
100°C. The denatured lysates were then split into two
equal aliquots which were incubated for 3 h at 37°C in
the presence or absence of 10 U of Endoglycosidase H
(New England Biolabs). Samples were then resolved on
7.5% SDS–PAGE followed by blotting onto nitrocellulose
membranes and probing with anti-DDR2 antibodies, as
described above.
Results
Clinical characteristics of SMED-SL patients
The parents are first cousins of Omani origin (Figure 1A).
The two affected children, a boy and a girl, were assessed,
aged 10 years and 7 years. Both presented with severe short
stature, height well below 3rd centile (−6SD-7SD) with rela-
tive macrocephaly, wide anterior fontanelle and partial alo-
pecia at the vertex. There was shortening of all limbs,
particularly the distal segments, madelung deformity of the
forearm with limited extension of the elbow joints, and
bowing of the tibias. The hands and feet were very small
with short stubby fingers and toes with hypoplastic nails
(Figure 1B panels (b) and (c)). The chest was narrow with
pectus excavatum and there was thoracic scoliosis with
lumber gibbus. The children had coarse facial features with
midface hypoplasia, hypertelorism, infraoribital fullness
with creases, short flat nose with wide anteverted nares,
long philtrum with prominent full lower lip, misaligned
teeth and micrognathia. Both had moderate conductive
hearing loss due to glue ear. The girl had progressive visual
impairment due to bilateral optic atrophy. Both children
have normal intelligence. Both parents, maternal and pater-
nal grandmother are said to be short but no measurements
were available.
Skeletal survey on both children revealed changes typ-
ical of SMED-SL including short and broad long bones
with irregular, flared metaphyses of the proximal and distalends with irregular trabecular structure (Figure 1B-f). In
the spine there was platyspondyly, pear shaped vertebrae,
anterior beaking, irregular endplates and punctate calcifica-
tion (Figure 1B-e). There was a small thoracic diameter
with short broad ribs. The tubular bones of the hands
were very short and broad with diaphyseal constriction
(Figure 1B-f ). The metacarpal bones were narrower at
the proximal than distal ends giving the appearance of
drumsticks and the distal phalanges were triangular in
shape (Figure 1B-d).
The patients have a homozygous truncating mutation in
the DDR2 gene
The genomic DNA from the parents and the male patient
was isolated and used as template to amplify all the DDR2
gene coding exons and splice sites. Direct sequence analysis
of the PCR amplicons revealed a homozygous two nucleo-
tide deletion in exon 18 (c.2468_2469delCT) of the patient
(Figure 2A). In addition to causing an amino acid substitu-
tion, S823C, the deletion leads to a frame-shift followed by
a stop codon two amino acid residues downstream of the
mutation (p.S823Cfs*2). Both parents were found to be het-
erozygous for the mutation (Figure 2A). The mutation is
predicted to result in a truncated DDR2 protein lacking the
C-terminal 32 amino acids of the cytoplasmic tyrosine kin-
ase domain. The serine residue at position 823 and the
amino acid residues in the truncated region of the mutant
are highly conserved across various species (Figure 2B).
This mutation has not been previously reported in any of
the SNP or clinical variant databases. Mutation prediction
programmes (Mutation taster) predicted that these changes
are highly likely disease-causing by affecting the protein
structure and/or function. Additionally, truncating muta-
tions occurring in the last exon of a gene are not sup-
pressed by nonsense mediated mRNA decay (NMD) and
might exert a dominant negative effect [38].
The mutation leads to defective intracellular targeting of
the mutant protein
Previously we reported that missense mutations located
on the intracellular kinase domain of DDR2 resulted in
the ER retention and loss of activation of the protein. To
investigate the implications of the novel disease-causing
mutation (S823Cfs*) on the DDR2 protein, we generated
by site directed mutagenesis, the mutant cDNA fused to an
HA epitope tag at the C-terminus and expressed it in a
mammalian expression system. The subcellular localization
of the mutant protein was determined by immunohisto-
chemical staining and confocal imaging of HeLa cells ex-
pressing the mutant protein. As expected, the wild type
DDR2 was found to localize primarily to the plasma mem-
brane and co-localize with the plasma membrane protein
H-Ras tagged with GFP (Figure 3, panels A,B and C). On
the contrary, the localization pattern of the S823Cfs*
Figure 1 Pedigree, dysmorphic features and radiographic findings in the affected family. (A) Pedigree of the consanguineous Omani
family. The family displays typical recessive modes of inheritance. Double bar represents consanguinity. Affected members are represented by
filled symbols. (B) Dysmorphic features (a) 10 year old affected boy, note short limbs, narrow chest and protuberant abdomen with everted
umbilicus (b) & (c) short broad hands and feet with stubby fingers and toes with short hypoplastic nails (d) X-ray of the left hand at 10 years of
age showing short and broad tubular bones with diaphyseal constriction, narrowing of the metacarpal bones proximally, triangular distal phallanges, and
irregular epiphyses which are cone shaped. L on the upper left corner of the X-ray refers to left hand (e) Lateral X-ray of the spine showing
platyspondyly with pear shaped vertebrae, some showing anterior beaking, irregularities of the vertebral endplated and punctate calcifications (f) X-ray of
the upper arm at 10 years of age showing mesomelic shortening of the long bones, madelung deformity, and irregular distal epiphyses of radius and ulna.
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shown in Figure 3 (panels D,E and F), the mutant protein
was found to localize predominantly in the endoplasmic
reticulum, along with calnexin. A fraction of the wild type
protein was also found to co-localize with the ER marker
calnexin (Figure 3, panels G,H and I); this is presumably
the in transit biosynthetic fraction of the protein or the
fraction that failed the stringent ER quality control ma-
chinery. In cells co-transfected with GFP-H-Ras and the
S823Cfs* mutant, the fluorescence from the mutant was
found to be excluded from the plasma membrane (Figure 3,
panels J,K and L).Incomplete glycosylation and loss of activation of the
disease-causing mutant
In all the previously reported SMED-SL missense mu-
tants of DDR2, collagen mediated activation was dis-
rupted due to either mis-folding and trafficking defects
or loss of ligand binding. The new disease-causing muta-
tion in this report is predicted to result in a truncated
protein which lacks the last 32 amino acid residues of
the cytoplasmic tyrosine kinase domain. To determine
whether the novel disease-causing mutant was functionally
active in vivo, we expressed the mutant and wild-type
DDR2 in HEK-293 cells and analyzed their N-glycosylation
status and activation by collagen.Due to glycosylation, DDR2 is often detected as a
mixture of 3–4 bands between 125 kDa and 130 kDa
[22,39,40], with the higher molecular weight forms
representing heavily glycosylated mature protein and the
smaller molecular weight bands corresponding to imma-
ture, partially glycosylated forms. In Western blot of ly-
sates from HEK-293 cells overexpressing the S823Cfs*
mutant, only the lowest molecular weight form was de-
tected which was also found to migrate faster than the
corresponding band in the wild type (Figure 4A, lower
panel). The highest and intermediate molecular weight
forms were not observed for the mutant while the wild
type DDR2 was detected as a mixture of three bands in-
cluding the highest and intermediate molecular weight
forms. Based on previous reports, the lower molecular
weight form of the mutant is presumably the ER retained
partially glycosylated folding intermediate. This was further
supported by deglycosylation of the mutant protein with
Endoglycosidase H (Endo H), which specifically removes ol-
igosaccharides of the high mannose and hybrid (pre-Golgi)
forms, but not complex carbohydrate structures attained in
the Golgi. Figure 4B shows the Endo H treated protein
extracts from wild type and mutant over-expressing
cells. The mutant protein was found to be sensitive to
Endo H as was the lowest molecular weight wild type form.
Deglycosylation caused both the forms to resolve as lower
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Figure 2 Identification of a novel dinucleotide deletion in the SMED-SL patient. Direct sequencing analysis was carried out for all the
coding exons of the DDR2 gene. (A) This panel shows a representative chromatogram of the DNA sequences indicating the c.2468_2469delCT
mutation in the affected individuals and their parents. Arrows indicate the position of the c.2468_2469delCT mutation in the patient and one of
the heterozygous carriers (B) Multiple sequence alignment of mutant and wild type DDR2 proteins from different species. The S823 residue
is highlighted.
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Endo H treatment. This confirms the ER localization of
the mutant which was also evident from the confocal
images (Figure 3).
Only the completely glycosylated and mature forms
of DDR2 of the highest molecular weight (130kDa) is
reported to reach the cell surface and get activated by
collagen [22,39,40], which is a prerequisite for DDR2
receptor-mediated signaling. Upon collagen binding,
DDR2 undergoes autophosphorylation at tyrosine residues
in the cytoplasmic domain. HEK-293 cells expressing wild
type or mutant DDR2 were treated with collagen as
described in the Methods section, and tyrosine phos-
phorylation was analyzed by Western blotting using
anti-phosphotyrosine (PY) antibodies. In contrast towild type DDR2, which, as expected, showed a strong
collagen-induced phosphorylation signal, no phosphor-
ylation signal was detected for the S823Cfs* mutant
(Figure 4A). These data strongly suggest that the mutation
has led to loss of the DDR2 protein in vivo function.
Discussion
We report here the clinical findings and radiological fea-
tures of two siblings with SMED-SL and a novel DDR2
homozygous mutation. In addition to exhibiting the typ-
ical clinical and radiological features consistent with
SMED-SL, our patients had some phenotypic variations
between them. Progressive visual impairment and bilat-
eral optic atrophy were observed in one of the patients.
Abnormal eye movements and bilateral optic atrophy
Figure 3 Comparison of intracellular localization of DDR2 wild type and S823Cfs* mutant in relation with plasma membrane marker H-Ras
and ER marker calnexin. HeLa cells were co-transfected with C-terminally HA-tagged wild type or mutant DDR2 and EGFP tagged H-Ras constructs and
stained with anti-HA antibodies. (A) and (D) shows the localization patterns of WT and the mutant DDR2 proteins. (B) and (E) shows the localization of
the marker protein H-Ras to the plasma membrane. (C) shows co-localization of WT-DDR2 with H-Ras and (F) shows exclusion of S823Cfs*-DDR2 from the
plasma membrane. (G) and (J) show distribution of HA-tagged wild type DDR2 and S823cfs* mutant in HeLa cells transfected with the indicated construct.
(H) and (K) show the localization of the ER marker protein calnexin. (I) and (L) show the extent of co-localization of DDR2 proteins with calnexin.
For presentation purpose, images (G)-(L) were pseudocolored as either red (DDR2) or green (calnexin) using ImageJ software.
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phenotype could be attributed to the fact that DDR2 is a
plasma membrane RTK that functions as a collagen re-
ceptor to collagen II, a fibrillar collagen found in cartil-
age and the vitreous humor of the eye. Importantly the
eye is made up of 80% collagen. Although the involve-
ment of DDR2 in pathophysiologies related to the eye
is not characterized, there is molecular evidence thatDDR1 and DDR2 mRNAs and proteins are expressed
in corneal epithelial cells, keratocytes and endothelial
cells [41].
The disease-causing frame-shift mutation reported
here is located on exon 18 of the DDR2 gene, which is
the last coding exon. The frame-shift causes an amino
acid change of S823C and premature termination of
translation, two amino acid residues downstream of the
Figure 4 Defective cellular trafficking causes loss of collagen-
induced signalling for the DDR2-S823Cfs* mutant. Full-length
untagged wild-type DDR2 or S823Cfs* mutant were transiently
expressed in HEK-293 cells. (A) Cells were stimulated for 90 min at
37°C with rat tail collagen I at the indicated concentrations (in μg/ml).
Cell lysates were analyzed by SDS–PAGE and Western blotting. The blots
were probed with anti-phosphotyrosine (anti-PY) monoclonal antibody
4G10 (upper blot) or polyclonal anti-DDR2 antibodies (lower blot). (B)
Cell lysates were treated with Endoglycosidase H (H) or left untreated (−)
for 3 h at 37°C and analyzed by SDS–PAGE and Western blotting. The
blot was probed with polyclonal anti-DDR2 antibodies. The positions of
molecular markers (in kDa) are indicated. The experiments were carried
out twice with very similar results.
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at the last coding exons of genes are found to be clinically
relevant in several monogenic diseases. Transcripts of genes
carrying premature termination codons located at least 50
nucleotides upstream of the last intron, are targets of anmRNA surveillance mechanism known as nonsense medi-
ated decay (NMD). But mRNAs carrying the mutation in
the last exon escape this mechanism which results in trans-
lation of truncated proteins which may exert a dominant
negative effect even in the heterozygous carriers of the mu-
tant allele [38]. Recently it was shown that Hajdu-Cheney
syndrome, a rare skeletal disorder, is caused by heterozy-
gous mutations clustering to the last exon of the NOTCH 2
gene, which code for a truncated protein that acts in a
gain-of-function manner [42]. In a frame-shift mutation re-
ported in DDR1 gene, DDR1d, which is predicted to result
in a membrane anchored, kinase deficient receptor, the mu-
tant did not exert a dominant negative inhibition on the
normal allele [43]. To establish a dominant negative effect
for the novel DDR2 mutant, more detailed clinical, molecu-
lar and cellular analysis of the affected family is required.
The disease-causing mutation affects amino acid resi-
dues in the tyrosine kinase domain of DDR2. All kinases
adopt a very similar structure [44] and hence loss of 32
amino acids from the DDR2 C-terminus is likely to
affect protein stability, folding and plasma membrane
targeting. Most kinases have a C-terminal tail, but in the
case of DDR1 and DDR2, the catalytic kinase domains
are followed by very short C-terminal tails. A crystal
structure of the kinase domain of DDR1 shows that the
C-terminal amino acids that are commonly assigned to a
C-terminal ‘tail’ are actually part of an α helix in DDR1,
which tightly interacts with the rest of the domain [45].
Therefore in the highly similar DDR2, loss of the 32
amino acids from the tightly folded C-terminus is likely
to cause misfolding of the kinase domain and subse-
quent retention in the ER. Moreover, the high molecular
weight form of DDR2 has been reported to be inherently
unstable and dependent largely on glycosylation for effi-
cient trafficking to the cell membrane [40]. We show
here that the S823Cfs* mutant is retained in the ER and
fails to reach the plasma membrane. As expected, the
wild type protein localized predominantly to the plasma
membrane, and a fraction of the wild type protein was
observed also in the ER. Biochemical analysis of the mu-
tant and wild type protein confirmed their intracellular
distribution. The predominant form of mutant protein
expressed in cells is found to be the immature lower mo-
lecular weight forms characteristic of ER retained folding
intermediates. The wild type DDR2 exists as a mixture of
mature high molecular weight and lower molecular weight
intermediate forms. Further, the low molecular weight
Endo H sensitive S823Cfs* mutant was not phosphorylated
in response to collagen activation. Only the cell surface
expressed DDR receptors bind to collagen, which induces
phosphorylation of tyrosine residues in the cytoplasmic do-
main and downstream signalling [11]. Our results indicate
that the S823Cfs* mutation results in an ER retained pro-
tein which is inactive in vivo upon adding collagen to the
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ings that mutations affecting the kinase domain of DDR2
result in misfolding and defective trafficking of the protein
[7]. Our results also indicate that as predicted from the
crystal structure of DDR1, the C-terminal amino acids are
crucial for the stability of DDR2.
We have elucidated previously that missense muta-
tions occurring in DDR2 cause loss of function of the
protein through two mechanisms, namely retention of
the mutant proteins in the ER and loss of ligand binding
activity [7]. The ER has a sophisticated quality control
system that ensures trafficking of only mature proteins
in their native conformation. Misfolded proteins that fail
to conform to the ER quality control are retained in the
ER and subsequently targeted for degradation by the
ubiquitin/proteasomal machinery and have been impli-
cated in the pathogenicity of many congenital disorders
[31]. Recently it has been shown in a transgenic mouse
model of growth plate dysplasia, that chronic ER stress
is sufficient to cause decreased chondrocyte proliferation
and reduction in bone growth, without inducing any al-
terations to the architecture and organization of cartil-
age extracellular matrix [30]. Chronic ER stress due to
persistent accumulation of misfolded proteins has also been
proposed to be involved in the development of other condi-
tions including diabetes in some cystic fibrosis patients
[46]. Concurrent to this hypothesis, in SMED-SL patients
carrying DDR2 mutations encoding plasma membrane
expressed variants, the clinical symptoms were reported to
be less severe than in patients carrying DDR2 mutations
encoding ER retained variants [7].
Spondylo-meta-epiphyseal dysplasia is a severe form of
dwarfism with serious complications and for which no
effective treatment is available. A previous study [5] sug-
gested that SMED-SL should be included in the list of gen-
etic disorders causing death. In genetic diseases caused by
the impaired function of a single gene, various intercon-
nected pathways are affected, making the identification of
relevant pharmaceutical targets difficult. Accurately defin-
ing the consequences of underlying mutations is a chal-
lenge and prerequisite to envision targeted therapies to
congenital diseases. We have described here a novel
disease-causing mutation in SMED-SL, which results in
defective intracellular targeting and therefore loss of in vivo
ligand induced phophorylation of the DDR2 protein.
Conclusions
This study documents the clinical findings and radiological
features of two siblings with SMED-SL and a novel homo-
zygous truncating mutation in the DDR2 gene. The novel
mutation affects the intracellular trafficking of DDR2 and
consequently collagen induced activation of the receptor. In
addition, our findings illustrates that the C-terminal amino
acids are crucial for the stability of the DDR2 protein, sincethe novel mutation leads to loss of the C-terminal 32 amino
acids of the protein.
Competing interests
The authors declare no competing interests in the preparation or publication
of the data in this manuscript.
Authors’ contributions
BRA, LA and BL were responsible for the project conception and design of
experiments. AJ performed genetic analysis, PK and HX performed confocal
microscopy, biochemical assays and generated the figures. AAK, AAS, AG,
MAA and LAA conducted clinical evaluations and compiled data. PK, LA,
BRA, BL and HX wrote and edited the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors would like to thank the patients’ family for participating in this
research. We are grateful to Mr. Saeed Tariq for helping with confocal
microscopy imaging.
Funding
This work was supported by the United Arab Emirates University (Grant #
31 M092) to B.R.A. and the Biotechnology and Biological Sciences Research
Council, UK (Grant # BB/I011226/1) to B.L.
Author details
1Department of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos
University, Al koudh, 123, Muscat, Sultanate of Oman. 2Department of
Pathology, College of Medicine and Heath Sciences, United Arab Emirates
University, P.O. Box 17666, Al Ain, United Arab Emirates. 3National Heart and
Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
4Pediatric Ophthalmology, Sultan Qaboos University Hospital, Sultan Qaboos
University, Alkoudh, 123, Muscat, Sultanate of Oman. 5Department of
Paediatrics, College of Medicine and Heath Sciences, United Arab Emirates
University, Al Ain, United Arab Emirates.
Received: 16 March 2014 Accepted: 4 April 2014
Published: 11 April 2014
References
1. Borochowitz Z, Langer LO Jr, Gruber HE, Lachman R, Katznelson MB, Rimoin
DL: Spondylo-meta-epiphyseal dysplasia (SMED), short limb-hand type:
a congenital familial skeletal dysplasia with distinctive features and
histopathology. Am J Med Genet 1993, 45:320–326.
2. Langer LO Jr, Wolfson BJ, Scott CI Jr, Reid CS, Schidlow DV, Millar EA, Borns PF,
Lubicky JP, Carpenter BL: Further delineation of spondylo-meta-epiphyseal
dysplasia, short limb-abnormal calcification type, with emphasis on diagnostic
features. Am J Med Genet 1993, 45:488–500.
3. Smithson SF, Grier D, Hall CM: Spondylo-meta-epiphyseal dysplasia,
short limb-abnormal calcification type. Clin Dysmorphol 2009, 18:31–35.
4. Al-Gazali LI, Bakalinova D, Sztriha L: Spondylo-meta-epiphyseal dysplasia,
short limb, abnormal calcification type. Clin Dysmorphol 1996, 5:197–206.
5. Dias C, Cairns R, Patel MS: Sudden death in spondylo-meta-epiphyseal
dysplasia, short limb-abnormal calcification type. Clin Dysmorphol 2009,
18:25–29.
6. Bargal R, Cormier-Daire V, Ben-Neriah Z, Le Merrer M, Sosna J, Melki J,
Zangen DH, Smithson SF, Borochowitz Z, Belostotsky R, Raas-Rothschild A:
Mutations in DDR2 gene cause SMED with short limbs and abnormal
calcifications. Am J Hum Genet 2009, 84:80–84.
7. Ali BR, Xu H, Akawi NA, John A, Karuvantevida NS, Langer R, Al-Gazali L,
Leitinger B: Trafficking defects and loss of ligand binding are the underlying
causes of all reported DDR2 missense mutations found in SMED-SL patients.
Hum Mol Genet 2010, 19:2239–2250.
8. Vogel W, Gish GD, Alves F, Pawson T: The discoidin domain receptor
tyrosine kinases are activated by collagen. Mol Cell 1997, 1:13–23.
9. Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE,
Davis S, Goldfarb MP, Glass DJ, Lemke G, Yancopoulos GD: An orphan
receptor tyrosine kinase family whose members serve as nonintegrin
collagen receptors. Mol Cell 1997, 1:25–34.
10. Vogel WF, Abdulhussein R, Ford CE: Sensing extracellular matrix: an update on
discoidin domain receptor function. Cell Signal 2006, 18:1108–1116.
Al-Kindi et al. BMC Medical Genetics 2014, 15:42 Page 10 of 10
http://www.biomedcentral.com/1471-2350/15/4211. Leitinger B: Transmembrane collagen receptors. Annu Rev Cell Dev Biol
2011, 27:265–290.
12. Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R: Discoidin
domain receptor tyrosine kinases: new players in cancer progression.
Cancer Metastasis Rev 2012, 31:295–321.
13. Leitinger B, Kwan AP: The discoidin domain receptor DDR2 is a receptor
for type X collagen. Matrix Biol 2006, 25:355–364.
14. Xu L, Peng H, Wu D, Hu K, Goldring MB, Olsen BR, Li Y: Activation of the
discoidin domain receptor 2 induces expression of matrix
metalloproteinase 13 associated with osteoarthritis in mice. J Biol Chem
2005, 280:548–555.
15. Olaso E, Labrador JP, Wang L, Ikeda K, Eng FJ, Klein R, Lovett DH, Lin HC,
Friedman SL: Discoidin domain receptor 2 regulates fibroblast proliferation
and migration through the extracellular matrix in association with
transcriptional activation of matrix metalloproteinase-2. J Biol Chem 2002,
277:3606–3613.
16. Flynn LA, Blissett AR, Calomeni EP, Agarwal G: Inhibition of collagen
fibrillogenesis by cells expressing soluble extracellular domains of DDR1
and DDR2. J Mol Biol 2010, 395:533–543.
17. Labrador JP, Azcoitia V, Tuckermann J, Lin C, Olaso E, Manes S, Bruckner K,
Goergen JL, Lemke G, Yancopoulos G, Angel P, Martinez C, Klein R: The
collagen receptor DDR2 regulates proliferation and its elimination leads
to dwarfism. EMBO Rep 2001, 2:446–452.
18. Kano K, Marin de Evsikova C, Young J, Wnek C, Maddatu TP, Nishina PM,
Naggert JK: A novel dwarfism with gonadal dysfunction due to
loss-of-function allele of the collagen receptor gene, Ddr2, in the
mouse. Mol Endocrinol 2008, 22:1866–1880.
19. Kano K, Kitamura A, Matsuwaki T, Morimatsu M, Naito K: Discoidin domain
receptor 2 (DDR2) is required for maintenance of spermatogenesis in
male mice. Mol Reprod Dev 2010, 77:29–37.
20. Matsumura H, Kano K, Marin De Evsikova C, Young JA, Nishina PM, Naggert
JK, Naito K: Transcriptome analysis reveals an unexpected role of a
collagen tyrosine kinase receptor gene, Ddr2, as a regulator of ovarian
function. Physiol Genomics 2009, 39:120–129.
21. Carafoli F, Hohenester E: Collagen recognition and transmembrane
signalling by discoidin domain receptors. Biochim Biophys Acta 1834,
2013:2187–2194.
22. Leitinger B: Molecular analysis of collagen binding by the human
discoidin domain receptors, DDR1 and DDR2: identification of collagen
binding sites in DDR2. J Biol Chem 2003, 278:16761–16769.
23. Carafoli F, Mayer MC, Shiraishi K, Pecheva MA, Chan LY, Nan R, Leitinger B,
Hohenester E: Structure of the discoidin domain receptor 1 extracellular
region bound to an inhibitory Fab fragment reveals features important
for signaling. Structure 2012, 20:688–697.
24. Mihai C, Chotani M, Elton TS, Agarwal G: Mapping of DDR1 distribution
and oligomerization on the cell surface by FRET microscopy. J Mol Biol
2009, 385:432–445.
25. Noordeen NA, Carafoli F, Hohenester E, Horton MA, Leitinger B: A
transmembrane leucine zipper is required for activation of the dimeric
receptor tyrosine kinase DDR1. J Biol Chem 2006, 281:22744–22751.
26. Carafoli F, Bihan D, Stathopoulos S, Konitsiotis AD, Kvansakul M, Farndale
RW, Leitinger B, Hohenester E: Crystallographic insight into collagen
recognition by discoidin domain receptor 2. Structure 2009, 17:1573–1581.
27. Zhang Y, Su J, Yu J, Bu X, Ren T, Liu X, Yao L: An essential role of discoidin
domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte
maturation via modulation of Runx2 activation. J Bone Miner Res 2011,
26:604–617.
28. Lin KL, Chou CH, Hsieh SC, Hwa SY, Lee MT, Wang FF: Transcriptional
upregulation of DDR2 by ATF4 facilitates osteoblastic differentiation
through p38 MAPK-mediated Runx2 activation. J Bone Miner Res 2010,
25:2489–2503.
29. Khosravi R, Sodek KL, Faibish M, Trackman PC: Collagen advanced
glycation inhibits its discoidin domain receptor 2 (DDR2)-mediated
induction of lysyl oxidase in osteoblasts. Bone 2014, 58:33–41.
30. Gualeni B, Rajpar MH, Kellogg A, Bell PA, Arvan P, Boot-Handford RP, Briggs
MD: A novel transgenic mouse model of growth plate dysplasia reveals
that decreased chondrocyte proliferation due to chronic ER stress is a
key factor in reduced bone growth. Dis Model Mech 2013, 6(6):1414–25.
31. Chen Y, Bellamy WP, Seabra MC, Field MC, Ali BR: ER-associated protein
degradation is a common mechanism underpinning numerous monogenic
diseases including robinow syndrome. Hum Mol Genet 2005, 14:2559–2569.32. Ali BR, Jeffery S, Patel N, Tinworth LE, Meguid N, Patton MA, Afzal AR: Novel
robinow syndrome causing mutations in the proximal region of the
frizzled-like domain of ROR2 are retained in the endoplasmic reticulum.
Hum Genet 2007, 122:389–395.
33. Hume AN, Buttgereit J, Al-Awadhi AM, Al-Suwaidi SS, John A, Bader M,
Seabra MC, Al-Gazali L, Ali BR: Defective cellular trafficking of missense
NPR-B mutants is the major mechanism underlying acromesomelic
dysplasia-type maroteaux. Hum Mol Genet 2009, 18:267–277.
34. McCracken AA, Brodsky JL: Evolving questions and paradigm shifts in
endoplasmic-reticulum-associated degradation (ERAD). Bioessays 2003,
25:868–877.
35. Aridor M, Hannan LA: Traffic jam: a compendium of human diseases that
affect intracellular transport processes. Traffic 2000, 1:836–851.
36. Aridor M, Hannan LA: Traffic jams II: an update of diseases of intracellular
transport. Traffic 2002, 3:781–790.
37. Guerriero CJ, Brodsky JL: The delicate balance between secreted protein
folding and endoplasmic reticulum-associated degradation in human
physiology. Physiol Rev 2012, 92:537–576.
38. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE: Nonsense-mediated
decay approaches the clinic. Nat Genet 2004, 36:801–808.
39. Konitsiotis AD, Raynal N, Bihan D, Hohenester E, Farndale RW, Leitinger B:
Characterization of high affinity binding motifs for the discoidin domain
receptor DDR2 in collagen. J Biol Chem 2008, 283:6861–6868.
40. Phan TN, Wong EL, Sun X, Kim G, Jung SH, Yoon CN, Yang BS: Low stability
and a conserved N-glycosylation site are associated with regulation of
the discoidin domain receptor family by glucose via post-translational
N-glycosylation. Biosci Biotechnol Biochem 2013, 77:1907–1916.
41. Mohan RR, Wilson SE: Discoidin domain receptor (DDR) 1 and 2: collagen-
activated tyrosine kinase receptors in the cornea. Exp Eye Res 2001, 72:87–92.
42. Isidor B, Lindenbaum P, Pichon O, Bezieau S, Dina C, Jacquemont S, Martin-
Coignard D, Thauvin-Robinet C, Le Merrer M, Mandel JL, David A, Faivre L,
Cormier-Daire V, Redon R, Le Caignec C: Truncating mutations in the last
exon of NOTCH2 cause a rare skeletal disorder with osteoporosis.
Nat Genet 2011, 43:306–308.
43. Alves F, Saupe S, Ledwon M, Schaub F, Hiddemann W, Vogel WF:
Identification of two novel, kinase-deficient variants of discoidin domain
receptor 1: differential expression in human colon cancer cell lines.
FASEB J 2001, 15:1321–1323.
44. Lemmon MA, Schlessinger J: Cell signaling by receptor tyrosine kinases.
Cell 2010, 141:1117–1134.
45. Leitinger B: Discoidin domain receptor functions in physiological and
pathological conditions. Int Rev Cell Mol Biol 2014, 310:39–87.
46. Ali BR: Is cystic fibrosis-related diabetes an apoptotic consequence of ER
stress in pancreatic cells? Med Hypotheses 2009, 72:55–57.
doi:10.1186/1471-2350-15-42
Cite this article as: Al-Kindi et al.: A novel mutation in DDR2 causing
spondylo-meta-epiphyseal dysplasia with short limbs and abnormal
calcifications (SMED-SL) results in defective intra-cellular trafficking.
BMC Medical Genetics 2014 15:42.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
